New drug duo aims to shrink breast tumors before surgery
NCT ID NCT07393425
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of two targeted drugs (trastuzumab deruxtecan and pertuzumab) can shrink or eliminate HER2-positive breast tumors before surgery. About 50 women with stage II-III breast cancer will receive the drugs for three cycles. If the tumor responds well, they continue the same treatment; if not, they switch to a standard chemotherapy regimen. The goal is to see how many patients have no cancer left at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 + BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Jiaotong University School of Medicine affiliated Ruijin Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••